Escario GómezMGarcía-Trevijano CabetasMHerranz MuñozC, et al.Effectiveness and safety of first-line nivolumab-ipilimumab in metastatic renal cell carcinoma. J Oncol Pharm Pract2026.
2.
YuYChenNYuS, et al.Association of immune-related adverse events and the efficacy of anti-PD-(L)1 monotherapy in non-small cell lung cancer: adjusting for immortal-time bias. Cancer Res Treat2024; 56: 751–764.
3.
AckermanKAGanGMeyerC, et al.Measurement error and bias in real-world oncology endpoints when constructing external control arms. Front Drug Saf Regul2024; 4: 1423493.
4.
VissersPAJElferinkMAGBijlsmaMJ, et al.Recommendations and definitions for time-to-event endpoints using real-world data in oncology. ESMO Real World Data and Digital Oncology2025; 10: 100649.
